I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| epithelial cell | 6 studies | 25% ± 8% | |
| type I pneumocyte | 4 studies | 22% ± 6% | |
| squamous epithelial cell | 3 studies | 52% ± 14% | |
| enterocyte | 3 studies | 24% ± 4% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| epithelial cell | 6 studies | 25% ± 8% | |
| type I pneumocyte | 4 studies | 22% ± 6% | |
| squamous epithelial cell | 3 studies | 52% ± 14% | |
| enterocyte | 3 studies | 24% ± 4% |
Insufficient scRNA-seq data for expression of CDKN2B at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| breast | 91% | 1802.49 | 419 / 459 | 94% | 24.65 | 1051 / 1118 |
| lung | 99% | 1670.09 | 571 / 578 | 84% | 26.91 | 971 / 1155 |
| esophagus | 87% | 2749.58 | 1263 / 1445 | 79% | 31.45 | 145 / 183 |
| bladder | 90% | 594.71 | 19 / 21 | 73% | 25.91 | 370 / 504 |
| skin | 97% | 2108.28 | 1757 / 1809 | 66% | 22.53 | 311 / 472 |
| intestine | 76% | 2370.89 | 738 / 966 | 77% | 15.32 | 408 / 527 |
| uterus | 61% | 431.73 | 104 / 170 | 90% | 65.55 | 412 / 459 |
| prostate | 82% | 540.22 | 201 / 245 | 65% | 6.77 | 324 / 502 |
| adrenal gland | 66% | 323.40 | 170 / 258 | 64% | 8.31 | 148 / 230 |
| stomach | 47% | 285.32 | 167 / 359 | 78% | 14.88 | 224 / 286 |
| pancreas | 10% | 48.92 | 33 / 328 | 90% | 29.09 | 161 / 178 |
| adipose | 99% | 2222.52 | 1191 / 1204 | 0% | 0 | 0 / 0 |
| ovary | 18% | 84.83 | 33 / 180 | 78% | 13.77 | 335 / 430 |
| tonsil | 0% | 0 | 0 / 0 | 93% | 62.59 | 42 / 45 |
| spleen | 92% | 716.17 | 222 / 241 | 0% | 0 | 0 / 0 |
| muscle | 87% | 854.77 | 698 / 803 | 0% | 0 | 0 / 0 |
| brain | 11% | 55.51 | 289 / 2642 | 71% | 19.88 | 504 / 705 |
| blood vessel | 74% | 416.64 | 989 / 1335 | 0% | 0 | 0 / 0 |
| thymus | 8% | 35.11 | 55 / 653 | 63% | 8.17 | 379 / 605 |
| kidney | 10% | 51.64 | 9 / 89 | 58% | 7.72 | 520 / 901 |
| liver | 3% | 13.26 | 6 / 226 | 44% | 5.10 | 180 / 406 |
| eye | 0% | 0 | 0 / 0 | 14% | 0.94 | 11 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 10% | 0.98 | 3 / 29 |
| peripheral blood | 8% | 37.81 | 78 / 929 | 0% | 0 | 0 / 0 |
| heart | 6% | 26.76 | 49 / 861 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0030511 | Biological process | positive regulation of transforming growth factor beta receptor signaling pathway |
| GO_0008285 | Biological process | negative regulation of cell population proliferation |
| GO_0071560 | Biological process | cellular response to transforming growth factor beta stimulus |
| GO_0034097 | Biological process | response to cytokine |
| GO_0000079 | Biological process | regulation of cyclin-dependent protein serine/threonine kinase activity |
| GO_0071460 | Biological process | cellular response to cell-matrix adhesion |
| GO_2000045 | Biological process | regulation of G1/S transition of mitotic cell cycle |
| GO_0014070 | Biological process | response to organic cyclic compound |
| GO_0031670 | Biological process | cellular response to nutrient |
| GO_0001889 | Biological process | liver development |
| GO_0050680 | Biological process | negative regulation of epithelial cell proliferation |
| GO_0042326 | Biological process | negative regulation of phosphorylation |
| GO_0048536 | Biological process | spleen development |
| GO_0070316 | Biological process | regulation of G0 to G1 transition |
| GO_0060253 | Biological process | negative regulation of glial cell proliferation |
| GO_2000134 | Biological process | negative regulation of G1/S transition of mitotic cell cycle |
| GO_0090398 | Biological process | cellular senescence |
| GO_0030219 | Biological process | megakaryocyte differentiation |
| GO_0030858 | Biological process | positive regulation of epithelial cell differentiation |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0019901 | Molecular function | protein kinase binding |
| GO_0004861 | Molecular function | cyclin-dependent protein serine/threonine kinase inhibitor activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | CDKN2B |
| Protein name | Cyclin-dependent kinase inhibitor 2B Cyclin-dependent kinase 4 inhibitor B (Multiple tumor suppressor 2) (MTS-2) (p14-INK4b) (p15-INK4b) (p15INK4B) Cyclin-dependent kinase inhibitor 2B (p15) |
| Synonyms | hCG_28310 MTS2 |
| Description | FUNCTION: Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest. |
| Accessions | P42772 ENST00000380142.5 [P42772-2] K7PPU3 ENST00000276925.7 [P42772-1] Q5ZEY8 Q8NIA6 |
